Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments. Genetic testing is a laboratory method ...

Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...

Several factors — most notably, older age, treatment in the community setting , and a lower educational level in the area of residence — are associated with lower rates of microsatellite instability ...

Codon-specific KRAS mutations are predictive of an overall survival (OS) benefit for metastatic colorectal cancer (mCRC) patients treated with trifluridine-tipiracil (FTD/TPI; Lonsurf), according to a ...

Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens. Disease ...